Metamark Genetics, Inc. Announces New Chief Executive Officer

Metamark Genetics, Inc. Announces New Chief Executive Officer
CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Metamark Genetics, Inc., a privately held oncology molecular diagnostics company, announced today the appointment of Mark R. Straley as the company's President, Chief Executive Officer, and newest member of its Board of Directors. Kenneth E. Weg, a Metamark co-founder who previously served as interim CEO, will continue to serve as Chairman of the Board of Directors.

Mr. Straley brings twenty five years of experience to Metamark Genetics, Inc., as a proven General Manager with Sales and Marketing expertise in the Global Healthcare Industry. With particular focus on the Diagnostics and Diabetes markets, Mark has a demonstrated track record of increasing revenue and profitability. With both Fortune 100 company and start-up expertise, Mark has operated in multiple healthcare sectors in both developed and emerging markets.

Most recently, Mark was the Worldwide President of Johnson & Johnson's Diagnostics division accountable for $2B in revenue with global responsibility for sales, marketing, customer support and commercial operations. Mark joined Johnson & Johnson in 2005 as the Global Vice President of Marketing for the Diagnostics division. Prior to his assignment with J&J, Mr. Straley worked for such brand name companies as Bayer Healthcare and Abbott Laboratories where he held progressively responsible roles in sales, marketing and general management in several North American locations. Mark is a graduate of Miami University located in Oxford, Ohio with a Bachelor of Science in Marketing.

Kenneth E. Weg, Metamark's Chairman, stated, "Metamark is extremely fortunate to have attracted such a seasoned and successful diagnostics executive to serve as Chief Executive Officer. On behalf of the entire Company and Board of Directors, I welcome Mark to the team and look forward to his leadership."

When commenting on his decision to join Metamark, Mr. Straley stated, "There remains a significant unmet medical need among patients diagnosed with early-stage cancers and their physicians when considering the selection of the most appropriate treatment for that individual patient's tumor. The mission of Metamark is to empower personalized treatment decisions through innovative assays that report on the fundamental molecular determinants of metastatic risk. It is a rare opportunity to be able to join Metamark's team of world-renowned scientific and business leaders in pursuit of this mission."

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.

SOURCE Metamark Genetics, Inc.

 

 

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.